Previous 10 | Next 10 |
Aquestive Therapeutics Inc. (AQST) is expected to report $-0.11 for Q3 2023
WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the refinancing of its existing ...
WARREN, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
2023-10-09 10:20:46 ET More on Aquestive Therapeutics ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q2 - Re...
2023-09-22 19:18:44 ET Summary Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture significant market share from current standard (auto-injectors). At current prices I expect that upside ...
2023-09-20 12:35:22 ET More on Aquestive Seeking Alpha’s Quant Rating on Aquestive Therapeutics Historical earnings data for Aquestive Therapeutics Financial information for Aquestive Therapeutics Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Ca...
WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the developm...
2023-09-20 08:29:58 ET Exscientia ( EXAI ) +30% climbs as Merck KGaA joins AI drug discovery. Regulus Therapeutics ( RGLS ) +16% Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose Clinical Trial o...
FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years of age Prescription Drug User Fee Act (PDUFA) target goal date set for April 28, 2024 WARREN, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aquestive ...
2023-08-08 10:45:02 ET Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Conference Call August 08, 2023, 08:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice Presiden...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...